首页> 美国卫生研究院文献>BMC Urology >Preoperative lymphocyte-to-monocyte ratio predicts clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: a retrospective analysis
【2h】

Preoperative lymphocyte-to-monocyte ratio predicts clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: a retrospective analysis

机译:术前淋巴细胞与单核细胞比率预​​测膀胱移行细胞癌行根治性膀胱切除术的患者的临床结局:回顾性分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundInflammation is a critical component of tumorigenesis, and many cancers arise from sites of infection, chronic irritation, and inflammation. Inflammatory cytokines triggered by tumors alter hematologic components, including neutrophil, lymphocyte, and monocyte counts. The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios have been shown to be valuable prognostic markers in various types of cancers, including bladder cancer. Risk stratification based on clinicopathologic data is insufficient to support treatment-related choices in patients with bladder cancer. Novel prognostic markers are therefore needed. An elevated pretreatment lymphocyte-to-monocyte ratio (LMR) is reportedly associated with improved overall survival (OS) and a longer time to treatment recurrence (TTR) in some types of cancers. However, these data are lacking in patients with bladder cancer. The aim of the present study was to investigate the effect of the preoperative LMR on OS and TTR in a cohort of patients with bladder cancer.
机译:背景炎症是肿瘤发生的关键因素,许多癌症是由感染,慢性刺激和炎症部位引起的。肿瘤触发的炎性细胞因子改变血液成分,包括中性粒细胞,淋巴细胞和单核细胞计数。中性粒细胞与淋巴细胞的比例以及血小板与淋巴细胞的比例已被证明是包括膀胱癌在内的各种类型癌症的有价值的预后指标。基于临床病理数据的风险分层不足以支持膀胱癌患者的治疗相关选择。因此需要新的预后标志物。据报道,在某些类型的癌症中,较高的预处理淋巴细胞与单核细胞比率(LMR)与改善的总生存期(OS)和更长的治疗复发时间(TTR)相关。但是,膀胱癌患者缺乏这些数据。本研究的目的是调查术前LMR对一组患有膀胱癌的患者的OS和TTR的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号